Angiodynamics Intrinsic Value Calculation – AngioDynamics Reports Mixed Results, Updates FY24 Outlook
January 6, 2024
🌥️Trending News
ANGIODYNAMICS ($NASDAQ:ANGO): AngioDynamics, Inc., is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of peripheral vascular disease. The company recently released its earnings report for the fourth quarter of fiscal year 2024, with mixed results. While the company’s overall sales performance was strong, profits were disappointing. In response to the results, the company has revised its outlook for fiscal year 2024. Despite this setback, AngioDynamics remains confident in its growth prospects for the upcoming year.
AngioDynamics is optimistic that its product portfolio and focus on innovation will help drive future growth. The company has recently released several new products and technologies designed to improve patient outcomes and expand its reach into new markets. Going forward, the company is focusing on developing new products and services that will continue to drive sales and profits.
Market Price
On Friday, AngioDynamics reported mixed results and updated its outlook for fiscal year 2024. The stock price opened at $6.2 and unfortunately closed at $6.2, a plunge of 19.9% from last closing price of 7.8. As a result, the company’s market value dropped significantly after the announcement. Though the outlook for the upcoming year was not fully optimistic, the company remained hopeful that its strategic investments would be beneficial and would enable it to reach its overall goals. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Angiodynamics. More…
| Total Revenues | Net Income | Net Margin |
| 335.89 | 6.45 | -2.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Angiodynamics. More…
| Operations | Investing | Financing |
| -1.08 | 92.27 | -58.55 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Angiodynamics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 493.95 | 66.14 | 10.64 |
Key Ratios Snapshot
Some of the financial key ratios for Angiodynamics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.8% | 14.7% | -14.3% |
| FCF Margin | ROE | ROA |
| -1.4% | -7.4% | -6.1% |
Analysis – Angiodynamics Intrinsic Value Calculation
At GoodWhale, we have thoroughly analyzed the financials of ANGIODYNAMICS. Our proprietary Valuation Line has calculated the intrinsic value of each ANGIODYNAMICS share to be around $18.8. However, currently, the stock is trading at $6.2, meaning it is undervalued by 67.0%. This presents an opportunity for investors to take advantage of a potential upside as the stock’s price could potentially increase to match its value. AngioDynamics_Reports_Mixed_Results_Updates_FY24_Outlook”>More…
Peers
The competition between AngioDynamics Inc and its competitors is fierce. Each company is striving to be the best in the industry, and they are all fighting for market share. AtriCure Inc is a leading provider of surgical devices for the treatment of atrial fibrillation. LeMaitre Vascular Inc is a leading provider of products and services for the treatment of vascular diseases. NuVasive Inc is a leading provider of minimally invasive surgical products and services.
– AtriCure Inc ($NASDAQ:ATRC)
AtriCure, Inc. has a market cap of $2.1 billion as of 2022 and a return on equity of -7.05%. The company is a medical device company that specializes in the treatment of atrial fibrillation, or AFib. AFib is a type of irregular heartbeat that can lead to serious complications, including stroke. AtriCure’s devices are designed to correct the underlying cause of AFib, which is often an imbalance in the electrical signals that control the heart’s rhythm. The company’s products are approved for use in the United States, Europe, and Japan.
– LeMaitre Vascular Inc ($NASDAQ:LMAT)
LeMaitre Vascular Inc is a medical device company that develops, manufactures and markets medical devices for the treatment of peripheral vascular disease. The company’s products include endovascular and open surgical vascular devices. The company has a market cap of 1.01B as of 2022 and a ROE of 6.77%. The company’s products are used by vascular surgeons and interventionalists to treat aortic aneurysms, peripheral artery disease, venous disease and other vascular conditions.
– NuVasive Inc ($NASDAQ:NUVA)
NuVasive Inc is a medical device company that focuses on developing minimally invasive surgical products and procedures for spine conditions. As of 2022, the company has a market capitalization of 2.06 billion dollars and a return on equity of 0.29%. The company’s products are used in over 70 countries around the world and its procedures are performed on over 600,000 patients annually.
Summary
Its net sales and profits both declined year-over-year, while adjusted EBITDA increased substantially. Following the announcement, AngioDynamics’ stock price fell on the day of the release. Investors should consider the lasting impacts of the pandemic on AngioDynamics’ business before investing in the company. It will be important to monitor the company’s progress in adapting to the new economic environment and its ability to drive sales and profits. Analysts should also consider the competitive landscape and the potential impact of new product launches on AngioDynamics’ performance.
In addition, investors should pay attention to the company’s financial health and cash flow.
